Podcasts about pharmd

Today's episode of This Week in Pharmacy — #TWIRx is sponsored by Value Drug Company and explores two major forces reshaping pharmacy: the evolution of the community pharmacy business model and the expanding role of artificial intelligence in medication optimization and value-based care.   PART ONE: The Impact of the Cash-based Community Pharmacy   Special Guest: Rick Seipp, PharmD President, Value Drug Company Community pharmacy is entering a new era.   In Part One, Todd Eury sits down with Rick Seipp, PharmD, President of Value Drug Company, to discuss the continued evolution and expansion of independent community pharmacy and the many different business models emerging across the profession.   Independent pharmacy owners are increasingly evaluating new ways to build sustainable businesses while creating greater professional freedom for pharmacists. One of the most interesting developments is the growth of cash-based and cost-plus pharmacy models that reduce or eliminate dependence on traditional insurance reimbursement and PBM-controlled prescription economics.   These models can give pharmacy owners greater control over pricing, patient relationships, clinical services and the overall direction of their businesses — while allowing pharmacists to practice with significantly less interference from insurance companies and pharmacy benefit managers.   Two pharmacies in the Pittsburgh region are demonstrating how powerful this model can become: Blueberry Pharmacy — Kyle McCormick, PharmD has built Blueberry Pharmacy around a transparent, cash-based model designed to simplify prescription pricing and create a more direct relationship between the pharmacist and patient. Forward Rx Pharmacy — Brandon Antinopoulos, PharmD is another emerging example of how pharmacists can create innovative pharmacy businesses built around transparency, accessibility and freedom from many of the traditional constraints of third-party reimbursement.   Todd and Rick discuss what these models mean for the broader independent pharmacy marketplace and why community pharmacy may be moving toward a much more diversified future.   Sponsored by Value Drug Company, a pharmacist-led wholesale distribution partner committed to supporting the continued growth and independence of community pharmacy. https://lnkd.in/ehf76qUs PART TWO: AI-Powered Medication Optimization   Special Guests: Yoona Kim, PharmD, PhD Co-Founder & CEO, Arine Jenny Behan, PharmD Lead Clinical Pharmacist, Arine In Part Two, #TWIRx shifts from pharmacy business innovation to one of the most important developments occurring in clinical pharmacy: the use of artificial intelligence to optimize medication therapy at scale. Arine is an AI-powered medication optimization platform designed to improve patient outcomes and reduce healthcare costs by helping ensure patients receive the most effective and appropriate medications. Listen to This Week in Pharmacy — TWIRx on the Pharmacy Podcast Network across Apple Podcasts, Spotify, Amazon Music, iHeartRadio, YouTube and all major podcast platforms. Pharmacy Podcast Network — Amplifying the Voice of Pharmacy.

Can the Body Heal Itself? A Pharmacist and Naturopath Talk Pregnancy and Nutrition Dr. Randi Shannon said she was going to blow our minds, and she delivered! In this episode of MaternalRx, pharmacist Danielle Plummer, PharmD, sits down with Dr. Shannon, a traditional naturopath who uses Face, Tongue and Nail Analysis, an approach she describes as rooted in thousands of years of traditional medicine. Their conversation explores pregnancy preparation, nutrition, nausea and vomiting, minerals, essential oils, disease prevention, and Dr. Shannon's belief that the face, tongue, and fingernails can reveal clues about what is happening inside the body. The interview is followed by a commentary where Danielle puts her pharmacist hat on for an evidence-based debrief, examining several of the episode's most surprising claims and asking an essential healthcare question: What happens when an idea sounds biologically plausible, yet the clinical evidence has not been tested? Topics include Type 1 diabetes, Down syndrome, salt intake, peppermint oil in pregnancy, cholesterol, dietary oils, pharmaceuticals, nutrient requirements, and the important distinction between traditional naturopaths and licensed naturopathic doctors. This isn't a conversation about dismissing complementary medicine. It's about listening with curiosity while still asking important questions: What do we know? What don't we know? Where might an approach put a patient or pregnancy at risk, and where might it support the body's ability to heal? Stay through the end to hear Danielle's Takeaway! Section 1: Welcome and disclaimer Meet Dr. Randi Shannon What is a naturopath? Preparing the body for pregnancy Nausea in pregnancy and gut health What can fingernails tell us? Nutrients and claims about preventing or reversing disease What can the tongue reveal? What can the face reveal? Section 2: Evidence-Based Debrief Do we need exactly 60 minerals, 16 vitamins, 12 amino acids and 3 essential fatty acids? Is Type 1 diabetes created during the first trimester? Can Type 1 diabetes develop later in life? Can maternal nutrition reverse Down syndrome in utero? Peanuts, mold, aflatoxins and liver risk Peppermint essential oil during pregnancy Are Americans “undersalted”? Pharmaceuticals, synthetic drugs and side effects Cholesterol, dietary oils and reproductive health Traditional vs. licensed naturopaths Danielle's takeaway About Dr. Randi Shannon Randi Shannon, ND, is a Florida-based traditional naturopath known for her use of Face, Tongue and Nail Analysis. She works with clients virtually in Florida, across the United States and internationally. Learn more: TheBodyCan.com RandiShannon.com/face-tongue-nail-analysis/ (844) 275-1056 About the Host Danielle Plummer, PharmD, is a pharmacist, antepartum doula, and founder of Obstet-Rx. Also known as HG Pharmacist, she helps women navigate Hyperemesis Gravidarum and medication use in complex pregnancies through education, advocacy and personalized medicine. HGPharmacist.com LinkedIn: linkedin.com/in/daniellerplummer HG Support Group: facebook.com/HGClinicalSolutions Important Listener Note This episode contains health and medical claims made by a guest that may differ from or contradict current evidence-based medical guidance. The guest's statements represent her perspectives and should not be interpreted as endorsement by MaternalRx, Danielle Plummer, or the Pharmacy Podcast Network. The second half of the episode provides Danielle's evidence-based commentary on several of these claims. This podcast is for educational purposes and is not a substitute for individualized medical care. Patients should discuss medications, supplements, herbal products, essential oils, and other treatments with an appropriately qualified healthcare professional.

In this bonus episode of the NCS Podcast Hot Topics series, host Rich Choi, MD, continues his conversation with Andrew Webb, PharmD, with a preview of "Subarachnoid Hemorrhage: Clazosentan vs. Fasudil for Vasospasm Prevention (SAVIOR) Study: Study Protocol for a Prospective, Multicenter, Randomized Trial," published in Neurocritical Care. They review the history of nimodipine as the standard treatment for improving outcomes after aneurysmal subarachnoid hemorrhage and compare its mechanism with those of fasudil and clazosentan. Dr. Webb explains why fasudil is commonly used for vasospasm prevention in Japan and discusses previous research showing that clazosentan can reduce vasospasm without consistently improving functional outcomes when added to nimodipine. The conversation also explores how the SAVIOR trial will directly compare clazosentan and fasudil in a nimodipine-free population. They consider whether the trial could establish a preferred approach in Japan, what its results might mean for practice elsewhere and whether clazosentan may eventually have a role for selected patients who cannot tolerate nimodipine. The views expressed on the NCS Podcast are solely those of the hosts and guests and do not necessarily reflect the opinions or official positions of the Neurocritical Care Society.

In this episode of the NCS Podcast Hot Topics series, host Rich Choi, DO, is joined by Andrew Webb, PharmD, to discuss the article "Valproic Acid for the Management of Agitation in Neurosurgical Intensive Care Unit Patients," published in Neurocritical Care. Their conversation examines the complex causes of delirium and agitation in the neurocritical care setting, including neurologic injury, medication effects, sleep disruption and frequent clinical interventions. They review nonpharmacologic approaches to delirium prevention, current sedation strategies and the potential role of valproic acid as an adjunct when agitation remains difficult to control. They also discuss findings from the retrospective study, in which valproic acid use was associated with reduced requirements for opioids, benzodiazepines and dexmedetomidine, along with fewer positive agitation scores and less use of physical restraints. Dr. Webb reviews the medication's multimodal effects, potential adverse events and drug interactions, and patient populations that may benefit from its use. He also emphasizes the need for careful monitoring, eventual deprescribing and prospective research to clarify valproic acid's role in neurocritical care. The views expressed on the NCS Podcast are solely those of the hosts and guests and do not necessarily reflect the opinions or official positions of the Neurocritical Care Society.

What if your pharmacist could help optimize a patient's asthma treatment before their next clinic visit? On this episode of the BackTable ENT & Allergy Podcast, Dr. Basil Kahwash welcomes clinical pharmacist Dr. Joelle Ayoub to discuss how ambulatory care pharmacists can partner with ENT and allergy clinics to optimize asthma management. Dr. Ayoub shares her experience working in a family medicine clinic, collaborating with providers through referrals, reviewing medications, and providing direct patient education on inhaler use and disease management. --- Get the BackTable apphttps://www.backtable.com/app --- Timestamps 00:00 - Introduction02:40 - The Role of the Clinic Pharmacist05:04 - Teaching Patients and Improving Inhaler Technique12:36 - Choosing Inhalers and Applying Guidelines18:51 - Comparing MDI, DPI, and SMI Devices28:15 - Tracking Asthma Control and Monitoring Adherence33:55 - Inhaler Education and Overcoming Barriers40:00 - Using Social Media for Patient and Provider Education44:16 - Pharmacist Collaboration and the Future of Team Care50:58 - Answering Biologics Patient Questions53:15 - SMART Therapy and Digital Inhaler Advances55:19 - Wrap Up --- More about this episode They discuss common gaps in asthma care, with a focus on inhaler technique and medication adherence. Dr. Ayoub explains how device complexity, cost, and a patient's ability to use their inhaler can all affect treatment. She also reviews the major inhaler types, common technique errors, and what to consider when choosing the right device for each patient. With this, Dr. Ayoub shares practical approaches to adherence monitoring, asthma guideline updates, and biologic monitoring. Throughout, Dr. Ayoub emphasizes the benefits of multidisciplinary collaboration and how pharmacists can help bridge gaps in care for patients with asthma. --- Resources Joelle Ayoub, PharmD, BCACP, APh - https://www.westernu.edu/bios/?bio=jayoub --- BackTable ENT & Allergy is the go-to podcast for otolaryngologists, allergists, and head and neck surgeons. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

Insulin-resistant patients with type 2 diabetes who require high-dose therapy have long lacked a rapid-acting option concentrated enough for compact insulin pumps. New pharmacokinetic data on an ultra-rapid U-500 insulin aspart, alongside additional phase 3 results for a combined once-weekly insulin icodec-semaglutide regimen, both aim to close persistent gaps in insulin delivery for this population. In this episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, reviewed two studies addressing unmet needs in insulin therapy for type 2 diabetes.The investigational agent AT278 is a highly concentrated insulin aspart formulated at 500 units/mL, distinct from existing U-500 regular human insulin, which behaves more like an intermediate-acting product. In a single-center, randomized, double-blind, crossover euglycemic clamp study spanning body mass index from 25 to 38 kg/m², AT278 produced significantly faster absorption and a greater glucose-lowering effect within the first hour versus both standard U-100 insulin aspart and U-500 regular human insulin. The ultra-rapid pharmacokinetic and pharmacodynamic profile held consistent across the BMI range studied.Current U-500 regular insulin requires dosing 30 minutes before meals while simultaneously serving as basal and prandial coverage, complicating use in automated insulin delivery systems and limiting compatibility with smaller-volume pumps. A concentrated, rapid-onset formulation could allow patients with high insulin requirements to use compact pumps and extended-wear infusion sets without the absorption problems tied to large-volume subcutaneous depots. Drawn from an early-phase study, the findings position AT278 as a potential first ultra-rapid option for prandial dosing in this population, though regulatory approval for pump use remains undefined.Separately, the phase 3 COMBINE 4 trial evaluated a fixed combination of once-weekly insulin icodec (Awiqli) and semaglutide, known as IcoSema, against once-daily insulin glargine U-100 in 485 adults with type 2 diabetes and baseline A1C above 8%. Over 40 weeks, IcoSema reduced A1C by 3.32 percentage points versus 2.44 points with glargine, a between-group difference of 0.88 percentage points, while producing a 0.79 kg weight reduction compared with a 3.81 kg gain with glargine. Time in range reached 79.8% with IcoSema versus 64.5% with glargine, consistent with the mechanistic rationale of pairing glucagon-like peptide-1 receptor agonism with basal insulin to limit postprandial excursions.These results build on earlier COMBINE 1 through 3 data, which showed IcoSema achieving noninferior or superior A1C reduction, superior weight outcomes, and lower hypoglycemia rates versus comparators. A single weekly injection combining basal insulin with a GLP-1 receptor agonist could reduce treatment burden and consolidate pharmacy copays, though semaglutide exposure remains capped by concurrent insulin titration, averaging 0.66 mg in COMBINE 4. Whether either agent reaches United States practice, including reported uncertainty around a domestic IcoSema launch, will determine their eventual role in managing insulin-resistant type 2 diabetes.

This episode looks at some smart ways to regulate pharmacy when it comes to med spas and pop-up clinics — ways that won't cut patients off from their meds. We also look at the latest news on the thyroid-extract front, what's happening with peptide compounding, and a bill in California that could bode well for pharmacists nationwide. Then we talk with Kristen Jones, PharmD, from Pharmacists Mutual about how insurance companies view compounding, and why compounders are taking a bigger risk than they might realize if they're compounding peptides. Pharmacists Mutual: https://pmuw.com Join APC: a4pc.org/join Stay up to date on these topics and more at: a4pc.org/news

Pharmacists and Advocacy for Patients in Pain  Friday, August 21, 2026 What happens when patients living with chronic pain, their advocates, and the pharmacists responsible for dispensing opioid medications view the same healthcare system from very different perspectives? This special episode of This Week in Pharmacy brings together the Doctor Patient Forum's founders, Claudia A. Merandi and Bev C. Schechtman, with pharmacist and nationally recognized pharmacy advocate Dr. Shane Jerominski, PharmD—better known as “The Accidental Pharmacist.” The discussion follows a wave of social-media debate surrounding Claudia's use of the term “Harmacists,” which prompted responses from hundreds of pharmacists who felt the label misrepresented their professional responsibilities and the legal restrictions under which they practice. Rather than allow that controversy to deepen the divide, TWIRx created an opportunity for direct, respectful conversation. The purpose of this episode is to help pain-patient advocates better understand the limits pharmacists face when dispensing opioids—and to identify opportunities for pharmacists and patient organizations to advocate together for safe, compassionate and uninterrupted pain care. Five Legal and Supply-Chain Realities Affecting Opioid Dispensing Pharmacists have a federal “corresponding responsibility.” Under 21 CFR §1306.04, a controlled-substance prescription must be issued for a legitimate medical purpose. Pharmacists share legal responsibility with prescribers for determining whether a prescription is valid. Knowingly filling an illegitimate prescription may expose the pharmacist to federal penalties and professional discipline. Review the federal regulation. Schedule II prescriptions must satisfy strict requirements. Federal law generally requires a valid written or compliant electronic prescription before a Schedule II opioid may be dispensed. Emergency oral prescriptions are permitted only under limited conditions and require prescriber follow-up documentation. Schedule II opioid prescriptions cannot be refilled. Under federal law, every additional dispensing generally requires a new prescription. Partial fills are allowed only under specific circumstances, documentation requirements and time limits. Pharmacists cannot simply extend or refill opioid therapy when a patient or prescriber requests it. State laws add another layer of requirements. Depending on the state, pharmacists may have to verify prescriber authority, review prescription-monitoring information, validate electronic or security-form requirements, confirm identification, document partial fills, or comply with state-specific dispensing limitations. For example, California requires controlled-substance prescriptions to meet defined security and validity standards. California Board of Pharmacy guidance. Wholesaler monitoring can restrict a pharmacy's opioid supply. DEA-registered distributors must identify and report suspicious controlled-substance orders under 21 CFR §1301.74. National wholesalers therefore operate monitoring programs that may delay, limit or suspend shipments based on ordering patterns, geography, drug mix and internal thresholds. These controls are imposed upstream and can leave a pharmacy unable to obtain medication—even when the pharmacist believes a prescription is clinically and legally appropriate. Review the federal distributor requirements. These examples are not exhaustive. Pharmacists must navigate overlapping federal law, DEA requirements, state pharmacy and controlled-substance laws, prescription-monitoring systems, employer policies, payer rules, wholesaler restrictions and professional standards. Requirements also vary by state and by the circumstances surrounding an individual prescription. The Central Question How can pain-patient advocates and pharmacists move beyond blame and work together to address the policies, supply restrictions, staffing conditions and regulatory pressures that can interfere with appropriate care? This conversation explores: Why patients may interpret a refusal or delay as judgment, discrimination or abandonment Why pharmacists cannot treat a valid prescriber signature as automatic authorization to dispense How PDMP and risk-scoring information can influence clinical decisions The effect of corporate policies and wholesaler ordering controls The difference between professional judgment and stigma The communication failures that damage trust between patients, prescribers and pharmacists How advocacy organizations and pharmacists can pursue policy reform together Why patients deserve clear explanations, respectful treatment and continuity-of-care planning How pharmacists can remain vigilant without losing empathy for people living with pain About the Doctor Patient Forum The Doctor Patient Forum, founded by Claudia A. Merandi and Bev C. Schechtman, combines healthcare education, research, digital influence and patient advocacy to address the consequences of opioid-reduction policies and barriers to individualized pain care. Claudia A. Merandi is an advocate and educator whose work contributed to a Rhode Island law protecting access to pain management. Since 2016, she has built a growing national audience while documenting systemic harms experienced by patients and healthcare professionals. Bev C. Schechtman is a researcher, advocate and educator who examines opioid-reduction policies, prescription drug monitoring programs and surveillance technologies such as NarxCare. Her work helps patients understand and navigate an increasingly complex healthcare system. Learn more: The Doctor Patient Forum About Dr. Shane Jerominski, PharmD Dr. Shane Jerominski is a pharmacist, Navy veteran and nationally recognized pharmacy advocate known as “The Accidental Pharmacist.” In 2025, his professional peers selected him as one of the “50 Most Influential People in Pharmacy.” Through his influential social-media platform, Shane combines humor, candid commentary and frontline experience to advocate for safer working conditions, professional unity and meaningful reform throughout pharmacy practice. He is also a co-founder of The Pharmacy Guild and has become a prominent voice for pharmacists and pharmacy technicians nationwide. A Call for Collaborative Advocacy Patients should not be stigmatized because they require pain treatment. Pharmacists should not be vilified for complying with laws and professional obligations that can place their licenses and livelihoods at risk. Progress requires both communities to recognize that many barriers originate beyond the pharmacy counter. Patients, pharmacists, prescribers and advocacy organizations share an interest in policies that protect medication safety without denying appropriate, individualized care. The goal is not to determine which group has suffered more. The goal is to replace mistrust with understanding—and turn that understanding into stronger, unified advocacy. This episode is intended for education and discussion. It does not provide legal or medical advice, and regulatory requirements may differ by jurisdiction and circumstance.

What happens when decades of medical knowledge meet a personal mission to rethink wellness?Dr. Robert Beltran, MD, PharmD, FACS, joins I Am Refocused Radio to explore the intersection of modern medicine, natural ingredients, cognitive health, vitality, and healthy aging.With doctorate degrees in both pharmacy and medicine from the University of California, San Francisco, and board certification in Otolaryngology-Head and Neck Surgery and Facial Plastic and Reconstructive Surgery, Dr. Beltran brings a unique perspective to the wellness conversation.He also shares the journey behind Recomnd, the wellness brand he founded after years of research and his own experiences with health and recovery.In this conversation, we discuss how Dr. Beltran approaches preventative health, the relationship between science and nature, what consumers should understand about supplements, and why maintaining mental and physical vitality becomes increasingly important as we age.This is a conversation about more than adding another supplement to the cabinet. It's about understanding the body, asking better questions about wellness, and exploring what it means to survive, revive, and thrive.https://recomnd.com/

The PBM Reform Podcast, sponsored by APCI, welcomes John Vinson, PharmD, Chief Executive Officer of the Arkansas Pharmacists Association, for a timely conversation with host Greg Reybold about the management of the TRICARE pharmacy benefit.   Express Scripts administers pharmacy benefits for TRICARE, the Department of Defense healthcare program serving more than 9 million active-duty service members, military retirees, and family members. In fiscal year 2023 alone, TRICARE spent more than $8 billion on prescription medications.   Greg and John examine concerns surrounding Express Scripts' administration of the program, including shrinking pharmacy networks, reduced patient choice, questionable contractor reporting, specialty-drug delivery oversight, and the consequences for independent and rural pharmacies.   A 2025 Government Accountability Office investigation found that:   TRICARE's minimum network requirement fell from 50,000 to 35,000 pharmacies. The network had approximately 13,165 fewer pharmacies in late 2024 than in late 2022. An estimated 380,000 beneficiaries may have been forced to find another pharmacy. The Defense Health Agency relied heavily on contractor-submitted reports that contained inaccuracies. DHA had not consistently audited the data used to evaluate beneficiary access. GAO's two corrective recommendations remain open as of August 2026, although DHA has begun adding reporting and auditing requirements.   The episode also addresses higher 2026 prescription copayments. For most non-active-duty beneficiaries, home-delivery copays are now $14 for generic formulary drugs, $44 for brand-name drugs, and $85 for non-formulary medications. At retail network pharmacies, the corresponding 30-day copays are $16, $48, and $85.   Greg and John discuss whether PBM-driven network reductions represent true savings—or simply transfer costs, inconvenience, and access barriers to military families and the community pharmacies serving them.   Key discussion points Express Scripts' role in administering the TRICARE pharmacy benefit Pharmacy network contraction and beneficiary disruption Access challenges facing rural communities and military families Inaccurate contractor data and insufficient federal oversight Specialty-pharmacy delivery and monitoring concerns Rising 2026 copayments and pressure toward mail order Arkansas' leadership in challenging PBM vertical integration The need for transparency, accountability, adequate reimbursement, and patient choice   Important clarification: TRICARE is administered by the Department of Defense and is distinct from healthcare and pharmacy services operated by the Department of Veterans Affairs.   Sponsored by APCI — American Pharmacy Cooperative, Inc.   Sources: U.S. Government Accountability Office, TRICARE's 2026 pharmacy-benefit update, official 2026–2027 pharmacy costs.

Currently, annual influenza vaccination is recommended for everyone 6 months of age or older who do not have a contraindication, but vaccine uptake was suboptimal among adults and children during the most recent season. In anticipation of influenza season, tune into to this podcast featuring audio from a live webinar to listen as experts Mary Barna Bridgeman, PharmD, BCPS, BCGP, and Jana Shaw, MD, MPH, MS, FAAP, FPIDS, discuss the 2025-2026 influenza season and explore strategies to improve your confidence in optimizing influenza vaccine uptake for pediatric and adult patients. To download the accompanying slides, and view additional activities, visit the program page. Topics covered in this podcast include: Influenza Uptake and Viral Activity During the 2025-2026 Season Influenza Vaccine Selection The Influenza Vaccine Dosing Algorithm for Children Aged 6 Months Through 8 Years Comparative Analysis of Immune Response to Seasonal Inactivated Influenza Vaccines Preferential Recommendations for Older Adults Strategies to Improve Outcomes for the 2026-2027 Season Get access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify. Presenters: Mary Barna Bridgeman, PharmD, BCPS, BCGP Clinical Professor Ernest Mario School of Pharmacy Rutgers, The State University of New Jersey Piscataway, New Jersey Internal Medicine Clinical Pharmacy Specialist Robert Wood Johnson University Hospital-New Brunswick New Brunswick, New Jersey Jana Shaw, MD, MPH, MS, FAAP, FPIDS Professor of Pediatrics, Public Health, and Preventive Medicine Pediatric Infectious Diseases Hospital Epidemiologist, Upstate Golisano Children's Hospital SUNY Upstate Medical University Syracuse, New York Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Independent pharmacies need partners they can trust—and patients need a prescription-drug system that puts access ahead of profits. In this episode of This Week in Pharmacy, Todd Eury welcomes Rick Seipp, PharmD, President of Value Drug Company, to discuss the importance of choosing a dependable wholesale distribution partner. Following Smith Drug Company's announced operational transition, Value Drug Company is prepared to help affected independent pharmacy owners evaluate their purchasing, distribution and operational needs while developing an orderly transition that protects continuity of service. For more than 90 years, pharmacist-led Value Drug Company has supported community pharmacies through transparent pricing, dependable distribution, collective purchasing power and programs designed to improve efficiency, growth and profitability. Rick explains how the company will provide transition assistance and regional gatherings where pharmacy owners can speak directly with Value Drug Company leadership. The episode also features a follow-up conversation with patient advocate Bil Schmidtknecht about the continuing fight for Cole's Act. Named in memory of Bil's son, Cole, the proposed reforms seek to protect patients from unexpected formulary and coverage changes that can suddenly make essential medications unaffordable. “Patients can't afford more delays, and lives should never be collateral damage in a profit-driven system,” Bil says. The discussion examines PBM accountability, medication affordability and why families must receive meaningful notice before coverage changes place lifesaving treatments beyond their reach. TWIRx News: Week Ending August 14, 2026 Employers Are Moving Away from the “Big Three” PBMs A new employer survey points to growing disruption in the PBM marketplace. Forty-six percent of surveyed employers reported using a PBM outside CVS Caremark, Express Scripts and Optum Rx—up from 37% the previous year. Employers are increasingly seeking transparent pricing, access to claims data and greater control over prescription-drug spending. Read the Axios report FDA Delays Major iPLEDGE Changes Until November The FDA has postponed implementation of updated iPLEDGE REMS requirements from August 8 to November 15, 2026, to allow additional system testing. The forthcoming changes are intended to reduce burdens on patients, pharmacists and prescribers while maintaining safeguards surrounding isotretinoin. Read the FDA iPLEDGE update   Episode Resources Value Drug Company transition-support announcement Value Drug Company transition assistance: 1-866-226-1772 Patient Protector Modern Medical Mafia: PBM Reform Pharmacy Podcast Network About the Guests Rick Seipp, PharmD President, Value Drug Company Bil Schmidtknecht Patient advocate and father of Cole Schmidtknecht  

In this episode, Danielle Roman, PharmD, BCOP, and Jordan Hill, PharmD, BCOP, discuss optimal care for patients with HR-positive/HER2-negative breast cancer receiving newer oral targeted therapies. Their conversation addresses treatment selection across early-stage and metastatic disease, biomarker-informed decision-making, adverse event management, and practical strategies to help patients remain on therapy. Key topics include: Selecting and sequencing oral targeted therapies, including CDK4/6 inhibitors, PARP inhibitors, PI3K/AKT pathway inhibitors, and oral SERDs Identifying patients with high-risk early breast cancer and applying evidence from trials such as monarchE, NATALEE, and OlympiA Using biomarkers such as BRCA1/2, PIK3CA, AKT1, PTEN, and ESR1 to guide therapy in metastatic disease Monitoring and managing treatment-related adverse events, including neutropenia, diarrhea, hepatotoxicity, QTc prolongation, hyperglycemia, rash, stomatitis, anemia, nausea, and fatigue Using dose modification, supportive care, patient education, and proactive follow-up to improve adherence and persistence with oral therapy Incorporating oncology pharmacists and the multidisciplinary care team into ongoing treatment monitoring and patient support PresentersDanielle Roman, PharmD, BCOP Manager, Oncology Clinical Pharmacy Services Oncology Clinical Pharmacy Specialist Allegheny Health Network Pittsburgh, Pennsylvania Jordan Hill, PharmD, BCOP Clinical Pharmacy Specialist, Breast Oncology West Virginia University Cancer Institute Morgantown, West Virginia Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Access the full educational program: Link to full program:https://bit.ly/4gvZerW And be sure to try our Interactive Decision Support Tools for Early Breast Cancer and Selecting AKT or PI3K Inhibitors for Patients With Metastatic Breast Cancer. By answering just a few quick questions, you can see what 5 experts would recommend for specific patient scenarios. Early Breast Cancer:https://bit.ly/4gtUiUq AKT or PI3K Inhibitors in MBC:https://bit.ly/4qcyBvk Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Erin D. Michos, MD, MHS Severe hypertriglyceridemia (sHTG) affects more than 3 million people, but it often flies under the clinical radar.1-3 When triglycerides are at or above a 500 mg/dL threshold, it's no longer just an isolated lab value—it's a level of hypertriglyceridemia where the clinical implications change, and where a more careful evaluation for underlying causes and risk becomes important.4 That's why Dr. Charles Turck sits down with Dr. Erin Michos to discuss what sHTG is, why it's so important to identify, and how we can effectively manage this condition to improve patients' overall health and reduce complication risk. Dr. Erin Michos is a Professor of Medicine, Director of Women's Cardiovascular Health, and Associate Director of Preventive Cardiology at Johns Hopkins University School of Medicine. References: Saadatagah S, Larouche M, Naderian M, et al. Recognition and management of persistent chylomicronemia: a joint expert clinical consensus by the National Lipid Association and the American Society for Preventive Cardiology. Am J Prev Cardiol. 2025;22:100978. doi:10.1016/j.ajpc.2025.100978 Sanchez RJ, Ge W, Wei W, Ponda MP, Rosenson RS. The association of triglyceride levels with the incidence of initial and recurrent acute pancreatitis. Lipids Health Dis. 2021;20(1):72. doi:10.1186/s12944-021-01488-8 Sikora Kessler A, Baum SJ, Kutrieb E, et al. Rates …

Send us Fan MailSchedule an Rx AssessmentYour pharmacy has a bottleneck so naturally, you list a job! But what if the bottlenecks in your pharmacy come down to software, not staffing?On this episode of the Bottom Line Pharmacy Podcast, we sit down with Ross Miller of TJM Labs to break down:What a pharmacy AI bot actually isHow TJM's product suite has expanded beyond data entryWhat change management looks like when a bot starts taking on technician-level tasksAnd more!Stay connected with Ross Miller and TJM Labs:Ross Miller LinkedInTJM Labs WebsiteTJM Labs LinkedInTJM Labs Instagram Stay connected with us:FacebookTwitterLinkedInScotty Sykes – CPA, CFP LinkedInScotty Sykes – CPA, CFP TwitterBonnie Bond – CPA LinkedInBonnie Bond – CPA TwitterMore resources on this topic: Podcast - Becoming a Pharmacy GladiatorPodcast – Driving Independent Pharmacy Profitability in 2026 with Nicolette Mathey, PharmD, CEO of Atrium24Podcast – 2026 Quarter 2 Pharmacy UpdatePodcast – America 250, The history of Pharmacy, Q&A

In this podcast episode, James A. Davis, PharmD, BCOP, and Kelley L. Julian, PharmD, BCOP, discuss evidence-based strategies for managing smoldering and newly diagnosed multiple myeloma, including: Risk stratification and treatment selection for smoldering multiple myeloma Anti-CD38–based regimens for transplant-eligible and transplant-ineligible patients Clinical evidence supporting triplet and quadruplet therapies MRD assessment and response-adapted treatment strategies Frailty, transplant eligibility, and individualized treatment selection Subcutaneous anti-CD38 administration and premedication requirements Pharmacist-led supportive care, toxicity management, dose modification, and patient counseling Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Presenters:James A. Davis, PharmD, BCOP Clinical Pharmacy Specialist, Myeloma/Lymphoma The Medical University of South Carolina, Hollings Cancer Center Affiliate Assistant Professor MUSC College of Pharmacy Charleston, South Carolina Kelley L. Julian, PharmD, BCOP Hematology/BMT Pharmacy Supervisor PGY2 Oncology Pharmacy Residency Program Director Huntsman Cancer Institute, University of Utah Salt Lake City, Utah Link to full program: https://bit.ly/4qaRb7n Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

One of the most difficult—and least discussed—aspects of building a Consolidated Service Center (CSC) is securing executive support and capital investment.   Success depends on connecting strategy, financial value and patient outcomes to an organization's broader goals. Ganesh Chandran is joined by Dr. Akeem Bale, Vice President, Pharmacy Services at the University of Texas Medical Branch, and Dr. Laura Mark, Vice President of Pharmacy at Allegheny Health Network, to discuss the strategic, financial, and organizational steps that transformed a promising idea into an approved capital investment.  Guest Speakers:  Akeem O. Bale, PharmD, MS, MBA, BCPS, BCSCP Vice President, Pharmacy Services Program Director, PGY1/2 HSPAL Residency Program UTMB Health, Department of Pharmacy Services Laura Mark, MS, MHM, PharmD Vice President of Pharmacy  Allegheny Health Network   Host:   Ganesh Chandran, PharmD, MBA Pharmacy Executive  Vizient Pharmacy Enterprise Support    Show notes: [01:12] How each organization recognized that traditional pharmacy operations could no longer support future growth, expanding ambulatory care, and increasing operational complexity. Why long-term strategic planning, workforce challenges, and enterprise wide support became the driving forces behind pursuing a consolidated service center. [04:39] How successful business cases focus on organizational priorities such as patient access, financial performance, quality outcomes, and total cost of care instead of technology alone. Why demonstrating measurable value through pilots, standardization, and return on investment helps gain executive support for large scale transformation. [08:30] The importance of tailoring proposals to different executive stakeholders while building champions who can advocate for the vision. How early operational improvements and phased implementation can demonstrate value before construction or major capital investments begin. [10:24] Why breaking a consolidated service center strategy into manageable phases creates confidence among executive leaders and improves long term success. How responding to executive questions with refined financial models and scenario planning strengthens both the proposal and organizational trust. [13:12] How creating an enterprise wide pharmacy culture through standardization, trust, and shared leadership prepares teams for organizational change. Why establishing a one team philosophy before opening a new facility creates stronger collaboration and more sustainable operational success. [16:56] Practical advice for pharmacy leaders beginning their own consolidated service center journey, including learning from peer organizations and celebrating incremental progress. Why a consolidated service center should be viewed as an enabler of a broader pharmacy strategy that supports long term growth, scalability, and patient care rather than simply a new building.   Links and Resources: Pharmacy Enterprise Support   Subscribe Today! Apple Podcasts Spotify YouTube RSS Feed  

Socially vulnerable Medicare patients see dramatically better outcomes—such as fewer emergency department visits, fewer preventable hospital admissions, and 23.4% to 30% less use of high-risk medications—when their physicians take on full financial risk for their care compared with those in traditional fee-for-service Medicare. That's the core finding of a new study published in the June issue of Population Health, Equity & Outcomes, and the subject of this conversation between Ken Cohen, MD, chief medical officer for Optum Health, and host Sophia Humphreys, PharmD, vice president of health system strategy and innovation at The American Journal of Managed Care.

In a cobranded episode between Oncology On the Go, hosted by CancerNetwork®, and the American Society for Transplantation and Cellular Therapy's (ASTCT) program ASTCT Talks, Terri Lynn Shigle, PharmD, BCOP hosted Vinita Pai, PharmD, MS, BCPPS, who spoke about the use of CAR T-cell therapy for pediatric patients, focusing on acute lymphoblastic leukemia (ALL).After a brief overview of progress in the cellular therapy field and pediatrics' first and only FDA approved CAR T product since 2017, their discussion explored the following:Review of real-world practice and outcomes in ALLPediatric practical challenges including logistics, leukapheresis, and lymphodepletion chemotherapyStrategies for managing cell therapy toxicities in pediatricpatientsConsiderations for survivorship and long-term toxicitiesGaps in pediatric care and future directionsListen below or via your favorite podcast platform.ReferenceO'Leary MC, Lu X, Huang Y, et al. FDA approval summary: tisagenlecleucel for treatment of patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Clin Cancer Res. 2019;25(4):1142-1146. doi:10.1158/1078-0432.CCR-18-2035

In this episode of the NASP Podcast, Sheila Arquette, R.Ph., President & CEO of the National Association of Specialty Pharmacy (NASP), sits down with Dr. Caroline Girardeau, PharmD, MBA, PMP, BCPS, Pharmacy Program Director at the Accreditation Commission for Health Care (ACHC), to explore the evolving specialty pharmacy accreditation landscape. Together, they discuss the scope and value of comprehensive specialty pharmacy accreditation, examining how rigorous accreditation standards help improve patient safety, clinical outcomes, operational excellence, and the overall quality of care. They also highlight how specialty pharmacies can leverage accreditation as more than a requirement for participation in payer or limited distribution networks, using it as a strategic framework to drive continuous quality improvement, strengthen operations, and elevate the patient experience.

Skin conditions are among the most common reasons patients seek advice from healthcare professionals, creating frequent opportunities for pharmacist intervention and support. This course reviews common dermatologic conditions encountered in pharmacy practice, including eczema, poison ivy, and other minor skin conditions and infections, while exploring the pharmacist's role in screening, triage, treatment selection, patient counseling, and prevention. You will be better prepared to support evidence-based management of common skin conditions and help patients access appropriate dermatologic care. HOSTRachel Maynard, PharmDGameChangers Podcast Host and Lead, Clinical & Partnership Education, CEimpactGUESTJamie McConaha, PharmD, BCACP, CDCES, FCCPAssociate Professor of Pharmacy PracticeDuquesne University School of Pharmacy Pharmacists, REDEEM YOUR CPE HERE!CPE is available to Health Mart franchise members onlyTo learn more about Health Mart, click here: https://join.healthmart.com/PRACTICE RESOURCEReceive the exclusive Practice Resource to use as a reference guide for this episode by enrolling in the course. Click here to enroll!CPE INFORMATION Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe clinical features and management considerations for common skin conditions encountered in pharmacy practice.2. Explain the pharmacist's role in screening, triage, treatment selection, patient counseling, and prevention of dermatologic conditions.Rachel Maynard and Jamie McConaha have no relevant financial relationships to disclose.0.05 CEU/0.5 HrUAN: 0107-0000-26-307-H01-P Initial release date: 8/10/2026Expiration date: 8/10/2029Additional CPE details can be found here.

Skin conditions are among the most common reasons patients seek advice from healthcare professionals, creating frequent opportunities for pharmacist intervention and support. This course reviews common dermatologic conditions encountered in pharmacy practice, including eczema, poison ivy, and other minor skin conditions and infections, while exploring the pharmacist's role in screening, triage, treatment selection, patient counseling, and prevention. You will be better prepared to support evidence-based management of common skin conditions and help patients access appropriate dermatologic care.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Lead, Clinical & Partnership Education, CEimpactGUESTJamie McConaha, PharmD, BCACP, CDCES, FCCPAssociate Professor of Pharmacy PracticeDuquesne University School of PharmacyGET CE FOR LISTENING!Stay Compliant. Grow Clinically. Practice with Confidence. Pharmacist CE Subscription: All your CE in one convenient subscription.All episodes, CE, and Practice Resources for the GameChangers Clinical Update is included with your Pharmacist CE Subscription. But wait…there's even more!The Pharmacist CE Subscription includes: -  Compliance and licensure CE -  GameChangers Clinical Updates-  Practical continuing education across patient care topics *The subscription does not include microcredentials or certificates, which are available separately for pharmacists seeking specialized service training. Purchase Now!PRACTICE RESOURCEReceive the exclusive Practice Resource to use as a reference guide for this episode by purchasing the Pharmacist CE Subscription. CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation to claim credit:If you are already enrolled in this course, click here to redeem your credit. To purchase the Pharmacist CE Subscription and claim your CPE credit, click here or to purchase this course individually, click here.  CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe clinical features and management considerations for common skin conditions encountered in pharmacy practice.2. Explain the pharmacist's role in screening, triage, treatment selection, patient counseling, and prevention of dermatologic conditions.Rachel Maynard and Jamie McConaha have no relevant financial relationships to disclose.0.05 CEU/0.5 HrUAN: 0107-0000-26-307-H01-P Initial release date: 8/10/2026Expiration date: 8/10/2027Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

In a cobranded episode between Oncology On the Go, hosted by CancerNetwork®, and the American Society for Transplantation and Cellular Therapy's (ASTCT) program ASTCT Talks, Terri Lynn Shigle, PharmD, BCOP, hosted Vinita Pai, PharmD, MS, BCPPS, who spoke about the use of CAR T-cell therapy for pediatric patients, focusing on acute lymphoblastic leukemia (ALL). After a brief overview of progress in the cellular therapy field and pediatrics' first and only FDA-approved CAR-T product since 2017, their discussion explored the following:·      Review of real-world practice and outcomes in ALL·      Pediatric practical challenges including logistics, leukapheresis and lymphodepletion chemotherapy·      Strategies for managing cell therapy toxicities in pediatric patients·      Considerations for survivorship and long-term toxicities·      Gaps in pediatric care and future directionsThe discussion highlighted the unique challenges of treating pediatric patients, paucity of data, and need for continued exploration of cellular therapy treatment not only in ALL, but other underlying diagnoses. Shigle is a clinical pharmacy specialist in the Stem Cell Transplantation & Cellular Therapy Department at The University of Texas MD Anderson Cancer Center. Pai is an associate clinical professor in the Division of Pharmacy Practice and Science at The Ohio State University.ReferenceO'Leary MC, Lu X, Huang Y, et al. FDA approval summary: tisagenlecleucel for treatment of patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Clin Cancer Res. 2019;25(4):1142-1146. doi:10.1158/1078-0432.CCR-18-2035

What happens when patients living with chronic pain do not have a pain pharmacist on their healthcare team? In this episode of This Week in Pharmacy, we explore the hidden clinical, emotional, and financial costs of managing pain without a pharmacist trained in pain management. These pharmacists do far more than review medications—they serve as accessible patient advocates, medication experts, care coordinators, and trusted partners for people navigating the complexities of chronic pain. Segment One: Pharmacists Are the Secret Weapon in Pain Management Special guest host Dr. Sing Ping Chow, PharmD, BCPMP, is joined by Dr. Matthew Hermenau, PharmD, BCPMP, CPh, NBC-HWC, CPT, for an important discussion about pharmacist-led pain management. Together, they examine how pain pharmacists can: Identify medication-related risks and opportunities to improve therapy Help patients balance pain relief, function, safety, and quality of life Collaborate with prescribers and other members of the healthcare team Support individualized, evidence-informed treatment plans Educate and empower patients living with chronic pain Advocate for patients whose concerns may otherwise go unheard Address the whole person—not simply a diagnosis or pain score The conversation reinforces a powerful message: pharmacists are one of healthcare's most underused resources in chronic pain care. When a pain pharmacist is part of the team, patients gain a knowledgeable advocate who understands medications, listens to their lived experiences, and helps them pursue safer and more effective care. Remembering Dr. Jeffrey Fudin This episode includes a special tribute to the late Dr. Jeffrey Fudin, PharmD, widely regarded as pharmacy's godfather of pharmacist-led pain management. Dr. Fudin was a pioneering clinician, educator, author, mentor, and tireless advocate for the meaningful inclusion of pharmacists in pain care. His work challenged conventional thinking, elevated the role of the pharmacist, and helped build a path for future generations of pain-management specialists. His influence continues through the pharmacists he mentored, the patients he championed, and the profession he inspired. We honor Dr. Fudin's legacy and his unwavering belief that people living with pain deserve informed, compassionate, and individualized care. Segment Two: The Nation's Best Hospital Systems In the second segment, we welcome Chelsey Wen, Senior Health Data Analyst with U.S. News & World Report, to discuss the newly released 2026–2027 Best Hospitals rankings. Chelsey explains how U.S. News evaluates hospital performance and how patients and families can use the findings when making healthcare decisions. The latest assessment evaluated nearly 4,500 hospitals across 14 adult specialties and 23 procedures and conditions. It places increased emphasis on patient outcomes and introduces regional specialty rankings designed to help patients locate complex care closer to home. Explore the 2026–2027 Best Hospitals announcement. link: https://health.usnews.com/best-hospitals Topics include: What it means for a hospital to be nationally ranked or rated “High Performing” The clinical data and patient outcomes considered in the evaluation Changes to the 2026–2027 rankings and methodology The importance of regional rankings and access to specialized care How patients should interpret hospital rankings when choosing where to receive care Sponsored By Today's episode of This Week in Pharmacy is brought to you by First Databank and Outcomes, pharmacy-technology organizations supporting safer, smarter, and more connected healthcare.

"A good way of thinking about this is this is the survival of the fittest clone. There could be a portion of a cancer that naturally has some resistance or ability to survive a particular drug. And over time, as the other cells around it are dying off, that particular clone is able to replicate and continue to survive in the face of that drug therapy and eventually take over as being the fittest clone. At that point, we're often seeing disease progression," Danielle Roman, PharmD, BCOP, manager of clinical pharmacy services at the Allegheny Health Network Cancer Institute in Pittsburgh, PA, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about resistance pathways.  Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD), including 30 minutes of pharmacotherapeutic content, by listening to the full recording and completing an evaluation at courses.ons.org by August 7, 2027. Roman has served on advisory boards for Genetech, Pfizer, Regeneron, and Daiichi Sankyo and received honoraria payments from Pharmacy Times and Decera for faculty lectures. These financial relationships have been mitigated. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report increased knowledge related to resistance pathways in oncology care. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Pharmacology 101 series Episode 423: Pharmacology 101: Interaction Pathways Episode 406: Drug Resistance Biomarkers and Their Impact on Cancer Treatment Choices ONS Voice articles: Predictive and Diagnostic Biomarkers Scientists Identify Protein Implicated in Tumor Growth, Treatment Resistance ONS book: Guide to Cancer Immunotherapy (second edition) Genomics and Precision Oncology Learning Library ONS Biomarker Database Pharmacogenomics Huddle Card CancerQuest: Cancer Drug Resistance National Comprehensive Cancer Network OncoKB.org Research To Practice To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "As we look at drug resistance, this is the concept that cancer cells are no longer able to respond to a cancer treatment. The downstream of this is that we could end up with progression of the disease and need to look at alternative therapies that may be beneficial for the patient. This is unfortunately a very common phenomenon. Drug resistance is a major cause of treatment failure and poor patient outcomes with treatments. Unfortunately, this is an issue we see that increases over time on treatment." TS 2:29 "Genetics play a really big role in drug resistance. We know that drug resistance can be due to different things. It could be epigenetics. It could be the tumor microenvironment factors. But genetics often play a very big role in resistance pathways. It's generally considered to be a critical contributor to resistance, particularly in the way of acquired variants to drug targets or amplifications of certain oncogenes that can lead cancers to have progression. A well-known genetic alteration is the BRCA1/BRCA2 variant that helps to make the cancer more efficient at fixing DNA damage. So we're trying to get DNA damage with chemotherapy, and this particular variant helps at fixing that damage to allow the cancer to progress. So that is one genetic variant we see that plays a big role in a number of different cancers." TS 4:51 "These pathways are not mutually exclusive. Oftentimes we have multiple resistance pathways involved. I think it's important to understand some of those individually, but kind of thinking about this as we might be facing multiple resistance pathways. ... We can see resistance mechanisms that vary based on the type of treatment we use, for example, traditional cytotoxic chemotherapy. We may be more likely to see some resistance mechanisms that are working at DNA: repairing broken DNA or working on those efflux pumps that are being used to push chemotherapy out of cells. If we're talking more about the targeted therapies such as tyrosine kinase inhibitors or monoclonal antibodies, we may be more likely to see resistance mechanisms that are what we discussed with that drug target alteration: changing the way that the target agents are able to bind to the tumor cells to activate or inactivate pathways so we may see some changes there." TS 12:39 "One way to overcome this and to help to decrease the resistance from developing is using combination therapy: drugs that are targeting different pathways at once or potentially using combinations with things like chemotherapy in addition to immunotherapy. In this way, as we're getting these different targets, we can hopefully decrease the mechanism of resistance that may be developing." TS 14:48 "Biomarker testing is an incredibly important part of our practice. In many situations now, we are getting upfront, comprehensive biomarker testing to identify whether the patient may have any of those intrinsic or primary resistance mechanisms that might make it so a patient is never going to respond to a particular type of treatment. And in that case, we can spare the patient from the potential toxicities of that treatment if we don't think that there's going to be benefit there. So I think that that has become a really important way that we can tailor patients for understanding what treatments are going to be more effective. And then after that, there's usually additional biomarker testing that may be warranted at the time of progression in certain types of cancer. And that really helps us to understand that acquired resistance that might be developing." TS 17:32 "Nurses are really helpful with filling in the gaps and bringing back patient concerns that might be shared with them. And these might be early signs of progression. Better understanding how our patients are feeling and what's going on with them may help us to identify a patient that we need to do some additional testing for to understand whether there is drug resistance ongoing and potential progression of disease." TS 21:52

We welcomed Nash Albadarin, PharmD, Associate Director of Clinical Programs at Judi Health™, back to the studio to talk about the evolution of clinical programs and clinical consulting for Episode 114 of Astonishing Healthcare! What happens when a proactive clinical consulting strategy is employed? What questions should employers ask to evaluate clinical programs? What sorts of results are we seeing with high-touch programs for low-cost alternatives or risk mitigation? Nash discusses his new role at Judi Health and answers these questions, and many more. A pharmacist by training with over 10 years of experience in the PBM industry, Nash describes what a consultative, data-driven approach to clinical programs looks like in practice, and he backs it up with data and real-world examples that show hundreds of thousands of dollars in savings and meaningful reductions in opioid exposure for employers. He also describes a new site-of-care optimization program that's turning heads.HighlightsProactive clinical strategies drive meaningful results and help build trust. For years, PBMs waited for clients to flag a spending problem before responding. Judi Health™ is flipping that model, scrutinizing claims data so the team can bring vetted solutions to the table or contact plan members before red flags appear.The results are concrete and substantial. Recent biosimilar conversions drove $130,000 in annualized member savings and $850,000 in annualized plan savings, while Rx Ally cut short-acting opioid day supply by 14.3 days for enrolled members.Shifting care from medical to pharmacy - and the site-of-care - yields surprising savings. A newer clinical program, CareShift Health, optimizes site-of-care and shifts select medical drugs to the pharmacy benefit, resulting in a lower net cost.Unified data unlocks hidden savings. Medical and pharmacy spend have traditionally lived in separate silos. When you compare them side by side, the excess billing and administration costs tied to provider-administered drugs become clear, and clients are often "blown away" by what they find.Related ContentAH043 - Pharmacy Benefits 101: DMP & MTM, Explained, with Nash Albadarin, PharmDHealth Benefits 101: The Importance of Clinical ProgramsReplay - Improving Metabolic Health in a GLP-1 WorldPoster: The Impact of Text Messaging and Pharmacist Outreach Interventions on Medication Adherence Rates in a Commercial PBM PopulationHow PBMs are tackling behavioral health (Managed HC Executive)For more information about this episode and content from Judi Health, visit www.judi.health/insights.

Today's Special Topic is The Role of Clinical Trials with experts Gray Kirby, PharmD, Dr. Katherine Ansley, Medical Oncologist with Atrium Health, and Dr. Kathleen Elliot, Medical Oncologist, Novant Health. Our experts addresses several questions including: What is a clinical trial? How do I find a clinical trial? Will my oncologist have access to a clinical trial? Who responsible for a clinical trial and who pays for it? Who protects my rights in a clinical trial?  How do I know what tests and procedures will be done on me during a clinical trial?  What are my commitments to the trial? How do I know if the trial is safe?  What are the potential benefits? How long does it take for a new drug to get on the market and what is the cost? To watch the recording, or see other expert interviews, visit https://cancerservicesonline.org/experts

Welcome to SuiteCast, a new podcast sponsored by SuiteRx Pharmacy Technology Platforms, exploring the strategies, technologies, and leadership practices helping pharmacies improve performance, expand patient care, and build sustainable revenue.   In this episode, we speak with Betsy P. Reynolds, PharmD, Director of Pharmacy Consulting and Partner at Method Healthcare, and Rodney Whittington, CEO and Partner at Method Healthcare.   Betsy and Rodney discuss how pharmacy leaders can identify operational inefficiencies, strengthen internal workflows, and develop clinical care programs that support both better patient outcomes and business growth. The conversation also examines new revenue opportunities within long-term care, geriatric pharmacy services, and pharmacy consulting.   Listeners will hear practical insights on evaluating current pharmacy operations, implementing scalable clinical programs, improving staff productivity, and aligning technology with the pharmacy's strategic goals.   Key Discussion Topics Identifying and correcting operational inefficiencies Building sustainable clinical care programs Creating new revenue through pharmacy consulting services Expanding into long-term care and geriatric pharmacy Improving workflow, staffing, and organizational performance Using pharmacy technology to support growth and patient care Preparing pharmacies for changing reimbursement and service models Featured Guests   Betsy P. Reynolds, PharmD Director of Pharmacy Consulting and Partner Method Healthcare breynolds@methodhc.com   Betsy Reynolds is an experienced pharmacy consultant who helps organizations improve pharmacy operations, develop clinical services, and implement strategies that strengthen financial and patient-care performance.   Rodney Whittington CEO and Partner Method Healthcare   Rodney Whittington provides strategic leadership and operational expertise to healthcare organizations seeking to improve performance, expand services, and develop sustainable models for growth.   Learn more about Method Healthcare at methodhc.com.   About SuiteCast   SuiteCast, sponsored by SuiteRx Pharmacy Technology Platforms, features pharmacy leaders, technology innovators, and industry experts discussing the tools and strategies shaping the future of pharmacy operations and clinical care.

Send us Fan MailSchedule an Rx AssessmentWhat if your pharmacy's biggest cash flow drain is sitting right there on the shelf?On this episode of the Bottom Line Pharmacy Podcast, we sit down with Jared Barton of Inventory IQ to break down:What "perpetual inventory" actually means and why most pharmacies aren't as dialed in as they thinkHow AI is helping inventory teams find outliers, clean data, and speed up analysisWhy chasing the industry average on inventory turns can put you out of businessHow to identify your top items by cost and set reorder points that free up real cash flowWhat a solid cycle count process looks like and how often you should be doing itAnd more!Stay connected with Jared Barton: Jared Barton LinkedInInventory IQ WebsiteInventory IQ FacebookInventory IQ Twitter (X) Inventory IQ LinkedIn Inventory IQ Instagram Inventory IQ YouTube Stay connected with us:FacebookTwitterLinkedInScotty Sykes – CPA, CFP LinkedInScotty Sykes – CPA, CFP TwitterBonnie Bond – CPA LinkedInBonnie Bond – CPA TwitterMore resources on this topic: Podcast - Becoming a Pharmacy GladiatorPodcast – Driving Independent Pharmacy Profitability in 2026 with Nicolette Mathey, PharmD, CEO of Atrium24Podcast – 2026 Quarter 2 Pharmacy UpdatePodcast – America 250, The history of Pharmacy, Q&A

In this episode of Mind the Meds, host Erica Marini, PharmD, MS, BCPS, welcomes Jenelle Hall Montgomery, PharmD, BCACP, CPP, a clinical pharmacist practitioner with Duke Neurological Disorders Clinic at Duke University Hospital, to discuss highlights from the Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting in Charlotte, North Carolina, where Montgomery was recognized as a Giant of Multiple Sclerosis. Before the CMSC discussion, Marini runs through a roundup of recent neurology news, including approval of at-home initiation dosing for lecanemab-irmb (Leqembi; Eisai, Biogen), fast track designation for remlifanserin (Acadia Pharmaceuticals) in Alzheimer disease psychosis, approval of the oral PCSK9 inhibitor enlicitide (Lipfendra; Merck), and phase 3 data on tavapadon (AbbVie) for Parkinson disease showing a lower rate of impulse control disorders than traditional dopamine agonists.The pharmacists then turn to CMSC sessions on off-label and evolving areas of MS care. They discuss growing interest in neurofilament light chain as a biomarker for tracking subclinical disease progression over time, along with the ongoing debate over when it is safe to discontinue disease-modifying therapy (DMT) in older, stable patients. Both note their practices generally begin this conversation around 60 to 65 years of age, factoring in radiographic and clinical stability over the preceding decade, and describe strategies such as tapering dosing frequency or switching to lower-efficacy agents rather than abrupt discontinuation.The conversation closes with an update on family planning in MS, where new data presented at CMSC reinforce the safety of anti-CD20 therapies during pregnancy and breastfeeding. Montgomery and Marini review a 10-year dataset of about 5000 pregnancies on ocrelizumab (Ocrevus; Genentech), a large safety analysis of ofatumumab (Kesimpta; Novartis Pharmaceuticals) showing no increase in birth malformations, and early transfer-into-breastmilk data on ublituximab (Briumvi; TG Therapeutics). They also touch on the limited but growing evidence for GLP-1 receptor agonists in patients with MS, noting no known drug interactions with DMTs and possible indirect benefit through weight-related disease modulation, though neither pharmacist currently prescribes GLP-1s for an MS indication.Key Takeaways:1. Neurofilament light chain is emerging as a useful, though not yet mainstream, biomarker in MS. Rather than a single value, tracking neurofilament light chain over time alongside clinical status may help identify subclinical disease progression, particularly in patients without clear relapses.2. DMT discontinuation in older, stable patients remains individualized, with most practices starting the conversation around 60 to 65 years of age. Clinicians weigh 10-year clinical and radiographic stability, and some patients opt for a gradual step-down in dosing frequency or a switch to a lower-efficacy agent rather than outright discontinuation.3. New pregnancy and breastfeeding safety data continue to support anti-CD20 therapies as a preferred family planning strategy in MS. A 10-year, 5000-pregnancy dataset on ocrelizumab, reassuring malformation data on ofatumumab, and early breastmilk transfer data on ublituximab are strengthening patient counseling conversations around conception, pregnancy, and postpartum DMT resumption.

Cannabinoid Hyperemesis Syndrome (CHS) continues to be a major clinical challenge in the emergency department. Patients present with severe abdominal pain, intractable vomiting, and significant fluid and electrolyte derangements. CHS often affects people who have been using cannabis routinely for months to years – it can be difficult for patients to understand that their symptoms are related to cannabis.  Today, emergency pharmacist Haley Burhans joins us to discuss first-line treatments, fluid management, discharge strategies, and how to navigate these tough bedside conversations. First-Line Therapies: Haldol vs. Droperidol Haloperidol (Haldol): Supported by the HAVOC trial (haloperidol vs. placebo), which showed a reduction in symptoms and ED length of stay. Droperidol: Highly effective alternative with similar dopaminergic mechanism of action. May carry a lower risk of extrapyramidal symptoms compared to haloperidol.  Capsaicin Cream: addresses the TRPV1 pathway thought to drive CHS. Patients often dislike it as it causes a burning sensation on the skin and can be inadvertently spread to eyes or face. Can be an option if symptoms persist after trying the above meds and hot showers aren't feasible.  Backup Options & Anti-Emetics Alternative Dopaminergic Agents: Metoclopramide or prochlorperazine can be used. Standard Anti-Emetics (e.g., Ondansetron): Serotonergic anti-emetics generally fail to address the underlying CHS pathway. However, a single dose of ondansetron given alongside a butyrophenone (haloperidol/droperidol) is reasonable if you suspect co-existing etiologies. QTc Prolongation Warning: Chronic vomiting leads to electrolyte depletion. Combining anti-emetics and haloperidol or droperidol increases the risk of QTc prolongation. Baseline EKG: Not strictly required for every low-risk patient, but strongly recommended for patients with multiple risk factors (e.g., co-ingestion/use of methadone, history of heart failure, or severe baseline bradycardia). Fluid Resuscitation & Electrolyte Management CHS patients can vomit to the point of severe dehydration and profound electrolyte/acid-base derangements. Fluid Selection: Normal Saline (NS): A solid choice for initial volume resuscitation when sodium and chloride are severely depleted. Lactated Ringer's (LR): Ideal as a follow-up or maintenance fluid because it contains a small amount potassium. Potassium Repletion: Oral repletion may not be tolerated in the acute setting. Consider IV potassium repletion in the ED, followed by oral home supplementation once nausea is controlled. Magnesium: While acute vomiting primarily drives potassium loss, consider IV magnesium if Mg is low or there is concern for QTc prolongation. Discharge Planning: What to Send Home Low-Dose Olanzapine ODT: Send the patient home with 2.5 mg Olanzapine ODT (orally disintegrating tablets). Why it works: It dissolves instantly on the tongue, bypassing the stomach, and provides extended dopaminergic coverage over the multi-day washout period.  Pharmacokinetics Pearl: Infrequent user THC half-life: ~1.3 hours (cleared in 5–6 hours). Chronic user THC half-life: THC accumulates in adipose tissue. In heavy users, therapeutic levels can persist for up to 2 weeks, driving prolonged receptor dysregulation even after cessation. Navigating the Bedside Conversation Explaining to a chronic user that their daily cannabis—the very thing they use to relieve nausea—is causing their illness requires empathy and validation. Explain the Neurological Link: Cannabis acts on receptors throughout the entire body, including the brain's nausea center and the nervous system of the gut. Chronic, heavy saturation can paradoxically overload these pathways. Validate Their Experience: Acknowledge how counterintuitive it feels: “I know it's hard to believe that something you've used for years to feel better is causing this, but long-term daily use can change how your body processes it.” Set Realistic Expectations: Reiterate that symptoms will not resolve overnight. Even after stopping, it takes time for the pathways to recalibrate. What do you find most helpful for treating CHS? How do you have these difficult conversaions with your patients? Share your experience with us on social media @empulsepodcast or at ucdavisem.com Hosts: Dr. Julia Magaña, Professor of Pediatric Emergency Medicine at UC Davis Dr. Sarah Medeiros, Professor of Emergency Medicine at UC Davis Guests: Haley Burhans, PharmD, Emergency Medicine Clinical Pharmacist at UC Davis Resources: Borgundvaag B, Bellolio F, Miles I, et al. Guidelines for Reasonable and Appropriate Care in the Emergency Department (GRACE-4): Alcohol use disorder and cannabinoid hyperemesis syndrome management in the emergency department. Acad Emerg Med. 2024 May;31(5):425-455. doi: 10.1111/acem.14911. PMID: 38747203. Rech MA, Shalaby M, Gage KA, Gottlieb M. Managing Cannabinoid Hyperemesis Syndrome. Ann Emerg Med. 2026 Jun;87(6):717-722. doi: 10.1016/j.annemergmed.2025.12.024. Epub 2026 Feb 3. PMID: 41632059. *** Thank you to the UC Davis Department of Emergency Medicine for supporting this podcast and to Orlando Magaña at OM Productions for audio production services.

In this episode, Ronda Lehman, PharmD, MBA, FACHE, President, Mercy Health Lima, discusses expanding access across rural communities, strengthening recruitment and retention, and using technology and team based care to improve the patient and provider experience. She also shares her perspective on leadership, operational excellence, and preparing health systems for long term growth.

Weight loss medications can bring the number on the scale down quickly—but are you losing fat, muscle or both? And why do some people feel weaker or less healthy even while the pounds are coming off?In this episode of Baptist Health Talk, host Johanna Gomez speaks with clinical pharmacy specialist Erin Dorval and physician assistant Lisa Davis about what GLP-1 medications such as Ozempic and Wegovy are doing inside the body, why muscle preservation matters and how resistance training and nutrition support healthier, more sustainable results.They discuss: Why rapid weight loss can include significant muscle loss  How GLP-1 medications reduce appetite and quiet “food noise”  Why resistance training should begin at the start of treatment  What “Ozempic face” really is—and what causes it  How protein, hydration and smaller portions may help manage side effects  Why medication dosage does not always need to keep increasing  The risks of rapid weight loss and unmonitored compounded medications  How pharmacists, cardiology teams and other providers can work together  Practical ways to build healthier habits without trying to change everything at once The goal is not simply to lose weight. It is to improve strength, function, metabolic health and long-term quality of life.Host:Johanna GomezAward-Winning Host & JournalistGuests:Erin Dorval, PharmD, CPhClinical Pharmacy SpecialistBaptist HealthLisa K. Davis, DMSc, PA-C, CLSPhysician AssistantBaptist Health Heart & Vascular CareIf you found this episode helpful, you may also enjoy:Weight Loss MedicationsWeighing the Options: Diet, Exercise and MedicationWeight Loss Medication vs Surgery: What to Know

Pediatric irritable bowel syndrome with constipation (IBS-C) can significantly affect quality of life and presents unique treatment and counseling challenges for patients and families. This course reviews evolving management strategies for pediatric IBS-C, including newly approved treatment options and practical considerations for therapy selection. You will be better prepared to evaluate treatment approaches and counsel families on the safe and appropriate use of therapy for pediatric IBS-C.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Lead, Clinical & Partnership Education, CEimpactGUESTChristopher Hartley, PharmD, BCPPSPediatric Clinical Pharmacy SpecialistThe Johns Hopkins Hospital Pharmacists, REDEEM YOUR CPE HERE!CPE is available to Health Mart franchise members onlyTo learn more about Health Mart, click here: https://join.healthmart.com/PRACTICE RESOURCEReceive the exclusive Practice Resource to use as a reference guide for this episode by enrolling in the course. Click here to enroll!CPE INFORMATION Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe current treatment considerations for pediatric IBS-C, including recently approved pharmacologic options.2. Compare factors that influence treatment selection and family counseling for pediatric IBS-C.Rachel Maynard and [Speaker] have no relevant financial relationships to disclose.0.075 CEU/0.75 HrUAN: 0107-0000-26-300-H01-PInitial release date: 8/3/2026Expiration date: 8/3/2027Additional CPE details can be found here.

Pediatric irritable bowel syndrome with constipation (IBS-C) can significantly affect quality of life and presents unique treatment and counseling challenges for patients and families. This course reviews evolving management strategies for pediatric IBS-C, including newly approved treatment options and practical considerations for therapy selection. You will be better prepared to evaluate treatment approaches and counsel families on the safe and appropriate use of therapy for pediatric IBS-C.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Lead, Clinical & Partnership Education, CEimpactGUESTChristopher Hartley, PharmD, BCPPSPediatric Clinical Pharmacy Specialist,The Johns Hopkins Hospital GET CE FOR LISTENING!Stay Compliant. Grow Clinically. Practice with Confidence. Pharmacist CE Subscription: All your CE in one convenient subscription.All episodes, CE, and Practice Resources for the GameChangers Clinical Update is included with your Pharmacist CE Subscription. But wait…there's even more!The Pharmacist CE Subscription includes: -  Compliance and licensure CE -  GameChangers Clinical Updates-  Practical continuing education across patient care topics *The subscription does not include microcredentials or certificates, which are available separately for pharmacists seeking specialized service training. Purchase Now!PRACTICE RESOURCEReceive the exclusive Practice Resource to use as a reference guide for this episode by purchasing the Pharmacist CE Subscription. CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation to claim credit:If you are already enrolled in this course, click here to redeem your credit. To purchase the Pharmacist CE Subscription and claim your CPE credit, click here or to purchase this course individually, click here.  CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe current treatment considerations for pediatric IBS-C, including recently approved pharmacologic options.2. Compare factors that influence treatment selection and family counseling for pediatric IBS-C.Rachel Maynard and Christopher Hartley have no relevant financial relationships to disclose.0.075 CEU/0.75 HrUAN: 0107-0000-26-300-H01-PInitial release date: 8/3/2026Expiration date: 8/3/2029Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

Listen in as our expert panel untangles the latest recommendations for using equations to estimate kidney function. You'll hear their insights on when and how to use creatinine, cystatin C, or both to help safely adjust medication doses in kidney disease.Special guests:Erin F. Barreto, PharmD, PhD, FCCM, FASN, BCCCPAssociate Professor of Medicine and PharmacyMayo ClinicTracy Anderson-Haag, PharmD, BCPS, BCTXPClinical Pharmacy Specialist-TransplantationResidency Program Director, PGY-2 Solid Organ TransplantHennepin HealthcareNone of the speakers have anything to disclose. This podcast is an excerpt from one of TRC's monthly live CE webinars, the full webinar originally aired in June 2026.

PBM Reform Podcast Sponsored by American Pharmacy Cooperative, Inc. (APCI) Host: Greg Reybold Special Guest: Ben Mudd, PharmD, Executive Director, Kentucky Pharmacists Association   Momentum for meaningful pharmacy benefit manager reform is building in Washington.   In this episode of the PBM Reform Podcast, host Greg Reybold welcomes Dr. Ben Mudd, Executive Director of the Kentucky Pharmacists Association, to examine the bipartisan Pharmacists Fight Back Act, H.R. 6610, and what its advancement could mean for patients, pharmacists, employers, and the future of independent pharmacy.   On July 22, 2026, the House Committee on Oversight and Government Reform reported the legislation favorably following a committee markup. Introduced by Chairman James Comer of Kentucky and Representative Jake Auchincloss of Massachusetts, the bill would establish new requirements for pharmacy benefit managers participating in the Federal Employees Health Benefits Program.   The proposed reforms would require participating PBMs to provide fair pharmacy reimbursement, apply manufacturer rebates toward reducing beneficiaries' prescription drug costs, prohibit patient steering to PBM-affiliated pharmacies, increase transparency, and establish penalties for noncompliance.   Greg and Ben discuss why the Federal Employees Health Benefits Program could become an important proving ground for broader PBM accountability and how federal action may influence commercial plans, state legislation, and future healthcare policy.   Episode Discussion   The conversation explores:   Why H.R. 6610 has attracted bipartisan support How PBM reimbursement practices threaten independent pharmacy sustainability The impact of patient steering and PBM-affiliated pharmacy networks Why manufacturer rebates should directly reduce patients' prescription costs What “fair reimbursement” must include to protect pharmacy access How enforcement provisions and financial penalties could improve accountability Kentucky's role in advancing pharmacy and PBM reform The connection between federal legislation and state-level advocacy What pharmacists should communicate to legislators and patients The remaining steps required before H.R. 6610 can become law   Dr. Mudd brings the perspective of a practicing community pharmacist and association executive who has worked extensively in pharmacy advocacy. A graduate of the University of Kentucky College of Pharmacy, he practiced in both chain and independent pharmacy settings before assuming leadership of the Kentucky Pharmacists Association.   Ben is running for Kentucky State Senate position this November. Lear more about his platform and issues most important: https://www.votemudd.com/meet-ben   Key Takeaway   PBM reform is no longer simply an industry debate. It is a patient-access, healthcare-affordability, pharmacy-choice, and community-infrastructure issue.   The Pharmacists Fight Back Act represents a significant federal effort to separate PBM compensation from practices that may increase drug costs, restrict patient choice, and financially disadvantage independent pharmacies. The legislation's advancement is an important milestone—but pharmacists must remain informed, engaged, and vocal as the bill moves through the legislative process.   Subscribe to the PBM Reform Podcast for continuing coverage of legislation, regulation, litigation, and advocacy shaping the future of pharmacy benefit management and community pharmacy.   The PBM Reform Podcast is sponsored by American Pharmacy Cooperative, Inc., supporting independent pharmacies and advocating for a more transparent, competitive, and patient-centered prescription drug marketplace.

Discover the essential contributions of pharmacists in patient care with We're Your Pharmacist, a monthly podcast from ASHP. This episode features Maria Blaze, mental health pharmacy practitioner at the Lt. Col. Luke Weathers, Jr. VA Medical Center in Memphis, Tennessee. She shares what inspired her to pursue a career in pharmacy and offers insight into the vital role pharmacists play in supporting patients.  The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Send us Fan MailSchedule an Rx AssessmentLive at McKesson Ideashare 2026, this episode features Ollin Sykes in conversation with Todd Eury on the Pharmacy Podcast Network. Ollin covers:The importance of monthly adjustments for receivables, inventory, and payablesThe risks of commingling multiple pharmacy entities on one balance sheet or P&LWhat pharmacy owners considering expansion, file purchases, or long-term care/home expansion need to have in place firstStay connected with us:FacebookTwitterLinkedInScotty Sykes – CPA, CFP LinkedInScotty Sykes – CPA, CFP TwitterBonnie Bond – CPA LinkedInBonnie Bond – CPA TwitterMore resources on this topic: Podcast - Becoming a Pharmacy GladiatorPodcast – Driving Independent Pharmacy Profitability in 2026 with Nicolette Mathey, PharmD, CEO of Atrium24Podcast – 2026 Quarter 2 Pharmacy UpdatePodcast – America 250, The history of Pharmacy, Q&A

In this episode of The Pharmacist's Voice Podcast, I talk with Ohio pharmacist Dan Krinsky about writing, co-authoring, and editing. This is Episode 22 in the Pharmacist Authors Series. Unlike most episodes in the series, our conversation does not focus on one specific book. Dan has written and edited many types of professional content, including continuing education and journal articles, newsletters, patient education materials, business proposals, and pharmacy reference resources. Dan first appeared on the podcast in Episode 133, when we discussed his pharmacy career and pharmacogenomics. This time, writing gets the spotlight. Dan shares practical advice for pharmacists, pharmacy students, pharmacy technicians, and pharmacy professors who want to begin writing or expand their writing experience. Dan's contact information, website, and social media links  Dan Krinsky BS, MS, RPh, FAPhA on LinkedIn https://www.linkedin.com/in/dan-krinsky-bs-ms-rph-fapha-a8537a/  Dan's email dkrinsky@educare-4u.com  EduCare4U, LLC website https://www.educare-4u.com  PGx101, LLC on LinkedIn https://www.linkedin.com/company/pgx101  The Pharmacist's Voice Podcast Episode 133 featuring Dan Krinsky About Dan Krinsky B.S., M.S., R.Ph., FAPhA (July 2026) Dan is business owner, educator, entrepreneur and pharmacist who is passionate about advancing patient care and the pharmacy profession.  He owns 2 businesses:  EduCare4U, LLC, (focused on education and patient care) and PGx101, LLC (focused on pharmacogenomics education and practice implementation).  Mr. Krinsky is currently a Professor at the LECOM School of Pharmacy, serving as a lecturer, committee member, and student advisor.  He is a Fellow of the American Pharmacists Association and an active member of the Medication Management Special Interest Group.  Other ventures include working with providers to optimize patients' drug therapy; professional writing; creation of certificate training programs, and new business development.  Mr. Krinsky is Editor-in-Chief and Section Editor for the American Pharmacists Association publication 'Handbook of Nonprescription Drugs:  An Interactive Approach to Self-Care.' Mr. Krinsky's areas of expertise include community pharmacy practice, drug information, patient counseling and education, OTCs, natural products, pharmacogenomics, and developing and implementing medication therapy and disease state management programs.  His primary professional goal is to 'pay it forward', finding ways to make the profession better for the next generation of pharmacists.     Questions and abbreviated answers from our conversation How did writing become part of your professional life? Dan's first major writing project was his master's thesis in pharmacokinetics. Writing did not come naturally at first, but he discovered that he enjoyed gathering information and turning it into something useful for an audience. How can someone decide whether writing is right for them? Start with a topic you care about. Identify the audience, look for gaps in available information, and find a mentor or support network. You do not need to work alone. Should new writers start small or go directly to writing a book? Dan recommends beginning with an article, newsletter, or another smaller project when possible. Smaller projects provide quicker feedback and help writers build skills and confidence. Someone who wants to start with a book should narrow the topic, identify the audience, create an outline, set deadlines, and seek feedback early. What has Dan written? His work includes newsletters, business proposals, patient advisory leaflets, consumer health information, journal and continuing education articles, and two co-authored point-of-care resources: the Natural Therapeutics Pocket Guide and the Drug-Induced Nutrient Depletion Handbook. He has also contributed to multiple editions of APhA's Handbook of Nonprescription Drugs as an author and editor. How are writing, co-authoring, and editing different? An author creates the content. Co-authors share responsibility and need clear roles, flexibility, and communication. An editor improves accuracy, organization, clarity, and usefulness while protecting the author's voice. When should an author involve an editor? As early as possible. An editor can help shape the audience, scope, outline, organization, and flow before the author invests months in the wrong direction. Early feedback is usually easier to handle than dozens of changes at the end. How can someone find a useful topic? Pay attention to recurring patient questions, conversations, media claims, and gaps in health information. The final product does not need to be a book. It could be an article, handout, script, social media post, or educational program. What keeps people from starting? Dan identifies three common barriers: waiting to become "the expert," fear of criticism, and lack of structure. Know what you know, recognize what you do not know, and build a network that can help fill the gaps. How can pharmacists develop a writing habit? Schedule writing time, set specific goals, work backward from deadlines, and use an accountability partner. A detailed outline makes a large project feel more manageable. Where can beginners find legitimate writing opportunities? Consider professional associations, colleges of pharmacy, health systems, community pharmacies, continuing education companies, consumer health websites, and digital health companies. Build a portfolio with writing samples, areas of expertise, testimonials, and other communication experience. How long should someone give writing before deciding it is not for them? There is no single timeline. A newsletter article may take a month; a book may take 12 to 18 months. Set realistic deadlines for each project, start small, and give yourself time to learn. What is Dan's final advice for aspiring authors? Find a mentor, be patient, expect revisions, learn from feedback, and enjoy the process. Writing may not be the right path for everyone, but it can be a meaningful way to educate patients, serve the profession, and create new opportunities. Pharmacist Authors Series Episode List 2025 Pharmacist Authors Series Part 1 of 3 (June) Episode 336 with Jerry Levin, PhD, LMT - Affirm Yourself: 15 Principles to Retrain the Voice in Your Head. Part 2 of 3 (July) Episode 340 with Ashley Walker, PharmD - Expanding Your Brilliance: Creating Effortless Abundance while Navigating Business and Motherhood https://amzn.to/418hdwx Part 3 of 3 (October) Episode 353 with Sandra O. Onye, PharmD - Winning Is in My DNA: 15 Minutes of Self-Reflection https://amzn.to/48KTtn3 2024 Pharmacist Authors Series Part 1 of 3 (June) Episode 282 with Steve Leuck, PharmD - A Pharmacist's Story An Authentic Tale of True Love, Family, Addiction, and the Practice of Pharmacy Part 2 of 3 (July) Episode 288 Helen Sairany, PharmD - The We You Don't See:  Understanding the Long Shadows of Trauma Part 3 of 3 (August) Episode 293 Kim Newlove with Publishing in Doses Co-Founders Janan Sarwar, PharmD and Theary Chhim, PharmD plus audio engineer, Julie Walthers. = 2023 Pharmacist Authors Series (Part 1 of 15) June 5, Introduction to the Pharmacist Authors Series (Episode 220) (Part 2 of 15) June 9, The Pharmacist's Voice ® Podcast Episode 221:  Interview with Salam Kabbani, PharmD about her book: COVID Long-Hauler:  My Life Since COVID (Part 3 of 15) June 12, The Pharmacist's Voice ® Podcast Episode 222:  Interview with audio engineer Julie Walthers from Whole Story Studio: https://www.wholestorystudio.com/  (Part 4 of 15) June 16, The Pharmacist's Voice ® Podcast Episode 223 Interview with Erin L. Albert, PharmD on her book The Life Science Lawyer Part 5 of 15) June 19, The Pharmacist's Voice ® Podcast Episode 224 Interview with Sue Ojageer, PharmD on her children's book The Pharma Heroes:  The Power of Precision Medicine (Part 6 of 15) June 23, The Pharmacist's Voice ® Podcast Episode 225: Interview with Tony Guerra, PharmD about his Pharmacist Residency and Career Series (8 books) (Part 7 of 15) June 26, The Pharmacist's Voice ® Podcast Episode 226:  Interview with Christina Fontana, PharmD about her book Moving Beyond the Counter:  Elevating into Heart-Centered Health Care through Entrepreneurship (Part 8 of 15) June 30, The Pharmacist's Voice ® Podcast Episode 227: Interview with Jade L. Ranger, PharmD, about her book Mustard Seed Mentality: Unscripted Pearls of Wisdom from a Wife, Mother, and Entrepreneur (Part 9 of 15) July 7, The Pharmacist's Voice ® Podcast Episode 229: Interview with RDML Pam Schweitzer, PharmD and her daughter Amy Graves about their children's book Alice and Jack Hike the Grand Canyon (Part 10 of 15) July 10, The Pharmacist's Voice ® Podcast Episode 230: Interview with Cory Jenks, PharmD about his book Permission to Care:  Building a Healthcare Culture That Thrives in Chaos (Part 11 of 15) July 14, The Pharmacist's Voice ® Podcast Episode 231: Interview with Donna Bartlett, PharmD about her book MedStrong:  Shed Your Meds for a Better, Healthier You - Aging Well Through Deprescribing  (Part 12 of 15) July 17, The Pharmacist's Voice ® Podcast Episode 232:  Interview with Frieda Wiley, PharmD about her book Telecommuting Psychosis:  From Surviving to Thriving While Working in Your Pajama Pants.  Plus, we touch on her 3 children's books in development. (Part 13 of 15) July 21, The Pharmacist's Voice ® Podcast Episode 233:  Interview with Tim Ulbrich, PharmD about his book Seven Figure Pharmacist:  How to Maximize Your Income, Eliminate Debt, and Create Wealth  (Part 14 of 15) July 24, The Pharmacist's Voice ® Podcast Episode 234:  Interview with LaQuoia Johnson, PharmD about her book How Rxacism Manifests Inside the Small World of Pharmacy (Part 15 of 15) July 28, The Pharmacist's Voice ® Podcast Episode 235:  Pharmacist Authors Series wrap-up (solo show) Kim's websites and social media links ✅ Monthly email newsletter sign-up link https://bit.ly/3AHJIaF  ✅ LinkedIn Newsletter link https://bit.ly/40VmV5B ✅ Business website https://www.thepharmacistsvoice.com ✅ Buy my book on amazon.com https://amzn.to/4iAKNBs   ✅ The Pharmacist's Voice ® Podcast https://www.thepharmacistsvoice.com/podcast ✅ Drug pronunciation course https://www.kimnewlove.com ✅ A Behind-the-scenes look at The Pharmacist's Voice ® Podcast © Online Course https://www.kimnewlove.com  ✅ LinkedIn https://www.linkedin.com/in/kimnewlove  ✅ Facebook https://www.facebook.com/kim.newlove.96  ✅ Twitter https://twitter.com/KimNewloveVO ✅ Instagram https://www.instagram.com/kimnewlovevo/ ✅ YouTube https://www.youtube.com/channel/UCA3UyhNBi9CCqIMP8t1wRZQ ✅ ACX (Audiobook Narrator Profile) https://www.acx.com/narrator?p=A10FSORRTANJ4Z ✅ Start a podcast with my coach, Dave Jackson from The School of Podcasting! Click my affiliate link: https://community.schoolofpodcasting.com/invitation?code=G43D3G  *New 12-4-25*   Thank you for listening to episode 372 of The Pharmacist's Voice ® Podcast. If you know someone who would like this episode, please share it with them!

Pediatric Narcolepsy Challenges, Opportunities, and Emerging Therapies On this episode host Amy Lugo, PharmD, BCPS, BC-ADM, FAPhA, FAMCP, Founder and CEO of LoneStar Health Solutions, is joined by Dr. Joshua Lennon, Assistant Professor at the University of Tennessee Health Science Center, to discuss the unique challenges of diagnosing and treating narcolepsy in children. They explore why pediatric narcolepsy is frequently misdiagnosed, the significant delays many patients experience before receiving an accurate diagnosis, and the impact untreated symptoms can have on learning, social development, and long-term health. The conversation also examines current FDA-approved treatment options, promising advances in orexin-targeted therapies, and the important role managed care professionals play in improving timely access to evidence-based care for children living with narcolepsy.

Could parasites be contributing to chronic fatigue, digestive issues, brain fog, or unexplained health symptoms? In this episode, Bryana Burken, pharmacist and physician liaison with Physicians Preference Pharmacy, is joined by Elaina Mango, Vice President of the Hotze Health & Wellness Center, to discuss common misconceptions about parasites, how exposure can happen in everyday life, and why these infections may be more common than many people realize. Bryana and Elaina explain how parasites can be acquired through pets, food, travel, standing water, and environmental exposure, not just poor sanitation. They discuss the wide range of symptoms parasites may cause, and explore why parasite testing can be challenging, why false negatives are common, and how providers often rely on a combination of clinical symptoms, medical history, and treatment response when evaluating possible parasitic infections. Bryana also explains the role of compounded medications, why customized formulations may be appropriate for some patients, and why working with an experienced healthcare provider is essential when addressing parasites and other chronic health concerns. Watch now and subscribe to our podcasts at www.HotzePodcast.com. To receive a FREE copy of Dr. Hotze's best-selling book, Hormones, Health, and Happiness, call 281-698-8698 and mention this podcast. Includes free shipping!

Matt Jarvis is the SVP of Strategy in Lockton's national pharmacy practice. He has a PharmD (Doctor of Pharmacy) and has worked in both retail and consulting pharmacy roles. Matt is a subject matter expert in understanding current pharmacy market pricing, supply chain, and medication delivery to the consumer. He leads the development and implementation of innovative clinical solutions that drive optimal management in specialty drugs for Lockton clients. Mentioned on the ShowConnect with Matt Jarvis, PharmD on LinkedIn here: https://www.linkedin.com/in/mjarvispharmdWould you like O'Brien or Matt to discuss your company's pharmacy benefit plan? Reach out here: Contact O'BrienMatt and O'Brien discussed alternatives like Amazon Pharmacy and Mark Cuban's venture, Cost Plus Drugs. Timestamps(00:00:00) – Matt Jarvis, PharmD joins his colleague O'Brien McMahon on the People Business Podcast(00:03:48) – What is the structure of a pharmacy plan and how does it differ from the medical plan? What are the common misconceptions?(00:05:43) – What a PBM is and why does it exist? Why isn't pharmacy handled through the regular health plan?(00:08:12) – Why don't drug manufacturers sell directly to health plans and what the steps are from drug creation to pharmacy purchase?(00:09:44) – What is a formulary?(00:13:09) – Why is there is a disconnect between doctors prescribing medications and what's actually covered by a plan?(00:14:37) – What is the role of drug reps in the overall pharmacy system?(00:18:43) – Is AI influencing how doctors prescribe medications?(00:19:54) – What role does the pharmacist plays in the current system? (00:21:18) – Do pharmacists have any ability to intervene or help patients navigate the formulary, or do they just dispense whatever is prescribe?(00:23:30) – What is prior authorization, and is it driven by clinical or financial outcomes?(00:27:36) – What are the different drug tiers and what qualifies a drug for each tier?(00:28:48) – What qualifies as a specialty drug?(00:30:20) – What is the difference is between prior authorization and step therapy?(00:31:40) – What role do generics in the current pharm landscape?(00:40:16) – Step therapy and biosimilars: how they each work(00:42:38) – Where does mail order fit into the pharmacy system?(00:48:00) – Rebates: the complicated and confusing system of paying for drugs(00:56:21) – Emerging PBMs and when it makes sense for clients to switch(00:59:33) – How can employers vet new-model PBMs when traditional rebate-heavy models look better on a spreadsheet?(01:02:59) – Closing thoughts from Matt Jarvis

Updated inflation projections are only part of the story when it comes to pharmacy planning. Host Carolyn Liptak is joined by Dr. Jeni Hayes and Dr. Amanda Frick, to discuss Vizient's Summer 2026 Spend Management Outlook and why utilization trends, reimbursement, ambulatory care, and the expanding pipeline of advanced therapies are becoming just as important as inflation when preparing health systems for 2027 and beyond.   Guest speakers: Jeni Hayes, PharmD, MS Pharm, BCPS Senior Clinical Manager, Market Insights & Forecasting Vizient Clinical Spend Management   Amanda Frick, PharmD, BCPS Senior Clinical Manager, Market Insights and Forecasting Vizient Clinical Spend Management   Host:    Carolyn Liptak, MBA, BS Pharm  Pharmacy Executive Director, Regulatory Compliance  Vizient Center for Pharmacy Practice Excellence     Show notes:  01:03 Why this year's Spend Management Outlook expands beyond inflation to include utilization, reimbursement, product mix, and operational readiness.  How pharmacy leaders can use these broader market signals to make stronger strategic and financial decisions.  01:54 The updated 2027 pharmaceutical inflation projection and why it increased from the previous forecast.  Why organizations should pair national benchmarks with their own purchasing data to improve budgeting accuracy.  03:28  Three major trends transforming pharmacy planning, including ambulatory growth, utilization, and enterprise collaboration.  Why these consistent themes are changing how health systems approach long term pharmacy strategy.  04:25 How new utilization analyses provide earlier insight into future pharmacy demand than inflation data alone.  Examples of shifting trends in oncology therapies and GLP 1 medications that are influencing operational planning.  05:34 Why GLP 1 growth is creating opportunities that extend well beyond pharmacy budgeting.  How retail pharmacy, specialty pharmacy, pharmacist led clinics, and medication management can strengthen patient care and organizational performance.  07:10 Why pharmacy has evolved into an enterprise wide capability that impacts access, reimbursement, and financial performance.  How stronger collaboration across pharmacy, finance, revenue cycle, and clinical teams supports future readiness.  08:03  Emerging pipeline trends, including continued oncology growth and the rise of advanced therapies.  Why cell therapies, gene therapies, and RNA based medicines require organizations to prepare differently than traditional medications.  08:53  How health systems are preparing months before therapy approval by building operational and clinical infrastructure.  Why advanced therapies demand coordination across pharmacy, laboratory, nursing, finance, and physician teams.  10:33  The expansion of advanced therapies into autoimmune, neurologic, cardiac, and rare disease treatment.  Why organizations must balance planning for both high cost therapies and therapies with growing patient demand.  11:44 How pipeline monitoring has evolved into a strategic planning tool rather than simply tracking approvals.  Why early preparation helps organizations identify operational gaps before new therapies reach the market.  12:36  Key takeaways on preparing for the future of pharmacy through utilization data, operational planning, and enterprise collaboration.  Resources available through the Spend Management Outlook Insights Hub to support local budgeting and long term strategy.    Links and Resources:  Vizient Spend Management Outlook Insight Hub    Subscribe Today! Apple Podcasts Spotify YouTube RSS Feed

Send us Fan MailSchedule an Rx AssessmentIt's mid-2026, and Scotty Sykes joins the Pharmacy Podcast Network to talk about where independent pharmacy stands at the halfway mark of the year. In this episode, Scotty walks through: Why now is the time for owners to get their books, margins, and cash flow in orderThe surge of cash-based revenue opportunitiesBolt-on business models like home care and central fillAnd more!Stay connected with us:FacebookTwitterLinkedInScotty Sykes – CPA, CFP LinkedInScotty Sykes – CPA, CFP TwitterBonnie Bond – CPA LinkedInBonnie Bond – CPA TwitterMore resources on this topic: Podcast - Becoming a Pharmacy GladiatorPodcast – Driving Independent Pharmacy Profitability in 2026 with Nicolette Mathey, PharmD, CEO of Atrium24Podcast – 2026 Quarter 2 Pharmacy UpdatePodcast – America 250, The history of Pharmacy, Q&A

Chris Antypas, PharmD and President of Asti's South Hills Pharmacy in Pittsburg, PA, along with his partners are launching Medesto Heath.  This totally new type of technology will allow pharmacist to combine prescription data, lab results, clinical notes and other health metrics and determine if the medications a patient is taking are actually working.  This is way more than adherence and MTM.  It is a totally new paradigm for pharmacy care.  Antypas is joined by Robyn Amberg who has known Antypas for several years and proposed this podcast.   

Skin cancer remains one of the most common cancers in the United States, making effective sun protection an important component of preventive care. This course reviews sunscreen best practices, common patient questions, and recent updates affecting sunscreen products, including the addition of a new active ingredient to the OTC sunscreen monograph. You will be better prepared to provide evidence-based recommendations on sunscreen selection, sun safety, and skin cancer prevention. HOSTRachel Maynard, PharmDGameChangers Podcast Host and Lead, Clinical & Partnership Education, CEimpactGUESTKendall Guthrie, PharmD, BCACPDirector of Co-Curriculum/Clinical Professor,UMKC School of Pharmacy Pharmacists, REDEEM YOUR CPE HERE!CPE is available to Health Mart franchise members onlyTo learn more about Health Mart, click here: https://join.healthmart.com/PRACTICE RESOURCEReceive the exclusive Practice Resource to use as a reference guide for this episode by enrolling in the course. Click here to enroll!CPE INFORMATION Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe current recommendations for sunscreen use and sun protection to reduce the risk of skin cancer.2. Explain pharmacist-relevant considerations for sunscreen selection, including formulation differences, active ingredients, and patient counseling.Rachel Maynard and Kendall Guthrie have no relevant financial relationships to disclose.0.075 CEU/0.75 HrUAN: 0107-0000-26-289-H01-PInitial release date: 7/27/2026Expiration date: 7/27/2029Additional CPE details can be found here.

The longevity industry is booming. Influencers are promoting this and that as promoting healthy aging, longevity, and healthspan, and it's hard for us, much less our patients, to make sense of it.  To be sure, we should always start by recommending exercise, nutritious foods, good sleep habits, and meaningful social interaction.  We wanted to go beyond that to talk about the promise and potential and risks/harms of "biohacks." Today we talk with Mahtab Jafari, PharmD, and John Newman, MD, PhD, and to discuss: How we clinicians should think about this movement, knowing many of our patients (and ourselves) also prize living as long as we can as healthy as we can, and at the same time acknowledge that a high quality of life, growth, and a meaningful life are possible with support in states of disability or dementia. How animal models can leading to promising therapeutics but must be tested in humans What it takes for a drug to obtain approval for longevity or healthspan indications when we cannot realistically wait around 40 years for a result We ask them to rate the evidence for many treatment on the scale of very promising, meh, or snake oil/avoid, including creatine, metformin, GLP1, SGLT2i, NAD+, testosterone/estrogen, red light therapy, rapamycin, and rodeola rosea. And I get to sing Wake Me Up by Avicii - an uplifting song with lyrics that could have multiple meanings - makes you think! -Alex Smith

Oncolytic viruses are a novel and effective way to treat cancers by infecting and destroying cancer cells, but clinical delivery necessitates creative strategies to account for the required safety protocols, deep-freeze storage, and rigorous clinical oversight. The University of North Carolina (UNC) Lineberger Comprehensive Cancer Center is a referral center for the only currently FDA-approved oncolytic virus therapy for cancer, talimogene laherparepvec, and its staff noticed that a common pain point for patients receiving this treatment is the extensive time spent in appointments. In this episode, CANCER BUZZ speaks with 2026 ACCC Innovator Award winner Morgan Gwynn, PharmD, BCOP, CPP, an Oncology Clinical Pharmacist Practitioner at UNC Lineberger, about her program's development of a pharmacist-led care model to make oncolytic virus treatments more efficient for patients and providers. By moving toxicity assessment, clinical review, and dose planning to pre-treatment telemedicine visits, the program reduced treatment time by more than 2 hours per session and helped decrease unnecessary clinic visits and drug waste. "Just because there's one way that things are done, [that] doesn't mean that's the only way things can be done...Finding creative solutions that benefit...the patient, the physician, and our pharmacy...was key." – Morgan Gwynn, PharmD, BCOP, CPP Guest: Morgan Gwynn, PharmD, BCOP, CPP Oncology Clinical Pharmacist Practitioner University of North Carolina Medical Center
 UNC Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina Resources: ACCC 43rd National Oncology Conference 2026 ACCC Innovator UNC Lineberger A Pharmacist-Led Strategy to Improve Care With Oncolytic Virus Treatments Heart and Healing: Embedding Pharmacists in Cardio-Oncology Clinics Oncology Pharmacy Virtual Office Hours Highlight Emerging Strategies for Implementing Bispecific Antibodies  

Dr. John Kim joins the show to discuss mold illness, cell danger response, mitochondrial dysfunction, chronic inflammation, and why many patients remain stuck despite following conventional detox protocols. Together, we explore how environmental toxins, infections, trauma, gut health, and cellular resilience all influence the body's ability to heal and what clinicians can do to better support lasting recovery.We dive into:Cell danger response and its role in chronic illnessHow mold toxins disrupt mitochondria, cell membranes, and energy productionWhy emotional trauma and chronic stress can drive immune dysfunctionThe connection between mold illness, gut health, and the microbiomeWhy some patients react poorly to glutathione, binders, and traditional detox protocolsAdvanced testing for mold illness, inflammation, and mitochondrial healthThe importance of supporting drainage pathways before detoxificationHow mycotoxins contribute to brain fog, fatigue, and neuroinflammationPractical strategies for addressing chronic mold exposure and supporting cellular healingWhy a personalized, root-cause approach leads to better long-term outcomes